PharmaBoardroom

Cătălin Radu of Bristol Myers Squibb (BMS) Romania explains how the Celgene acquisition is allowing the company to provide their expertise on a…

Petr Vaculík, country manager of PSI CRO, a privately owned Swiss clinical research organization (CRO), describes how the number of clinical trials…

Olga Starobová, medical director of Syneos Health Czech Republic, walks us through the steps put in place to ensure successful synergies during the…

With clinical trials having become extremely expensive to conduct, industry buzz around the potential of data and artificial intelligence (AI) to…

Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an…

László Attila, president of the Committee of Public Health of Romania, highlights the Committee’s efforts to mitigate the detrimental effects of…

Bing Xu, GM of Vital River Laboratories, shares the company’s development in the last 20 years; the challenges of advantages of their JV with…

Dr David Kershenobich Stalnikowitz, director-general of the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ) shares…

Annual numbers of new molecular entities (NMEs) and biologics license applications (BLAs) approved by the FDA's Center for Drug Evaluation and…

An overview of the types of new medicines recommended for approval by the European Medicines Agency (EMA) in 2019. Made with Visme Infographic…

According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials…

A new report from the UK BioIndustry Association (BIA) asserts that the UK biotech industry is booming, despite Brexit uncertainties. Financing…